[Skip to Content]
[Skip to Content Landing]
December 1990

Complete Response of Metastatic Basal Cell Carcinoma to Cisplatin Chemotherapy: A Report on Two Patients

Author Affiliations

Department of Medicine Division of Medical Oncology Evanston Hospital 2650 Ridge Ave Evanston, IL 60201

Arch Dermatol. 1990;126(12):1660. doi:10.1001/archderm.1990.01670360128037

To the Editor.—  Basal cell carcinoma (BCC) of the skin is a most common form of human cancer. Almost all of these carcinomas are slow growing and invariably present as local tumors. Occasionally though, they may behave more aggressively and metastasize to a variety of other organs.1 Recently, Pfeiffer et al2 extensively reviewed the systemic cytotoxic therapy of basal cell cancer. Their review indicates that this tumor is sensitive to a number of chemotherapeutic agents, including cisplatin.2 A review of their data indicates that there are only four reported patients with metastatic BCC who have received cisplatin therapy. Herein, I wish to report two additional patients who had complete response to the administration of this drug.

Report of Cases.—Case 1.—  This white man developed a BCC on the left upper lip at the age of 30 years. He underwent a number of surgical procedures and

First Page Preview View Large
First page PDF preview
First page PDF preview